What question did this study set out to answer?

This research aims to evaluate the safety and efficacy of omalizumab for treating asthma in children aged 6 to 11 years.

February 9, 2026BMC Pediatrics1 citationsOpen Access

Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials

YYYi Yang CFCuiyun FangHefei Institutes of Physical Science ZJZhongli Jiang

Key Points

This research aims to evaluate the safety and efficacy of omalizumab for treating asthma in children aged 6 to 11 years.
Systematic review of randomized controlled trials
Analysis of clinical outcomes in children with asthma
Comparison of omalizumab with placebo or other treatments
Omalizumab demonstrates significant improvements in asthma control compared to standard treatments.
Enhanced clinical outcomes observed in children aged 6-11 using omalizumab for allergic asthma.

Abstract

These results advocate for the use of omalizumab as an effective therapeutic option for children with allergic asthma aged 6-11 years, highlighting its potential to optimize asthma management and enhance clinical outcomes in this vulnerable age group. Further research is warranted to confirm these findings and explore long-term outcomes.

KI fragen

Bookmark

View Full Paper